Youjia Bio Recognized as a 2024 Hangzhou 'New Eaglet' Enterprise, Advancing into Clinical Development of Innovative siRNA Therapeutics
YOUJIA BIO
Nucleic Acid Drug Developer
As the National Day approaches, the Hangzhou Science and Technology Bureau announced the recognition results for the 2024 "New Eagle Enterprise." After a rigorous application and evaluation process, Youjia (Hangzhou) Biomedical Technology Co., Ltd. ("YOUJIA BIO") was successfully selected for this honor. This recognition not only affirms YOUJIA BIO’s technical strength and development potential but also marks authoritative approval of the company’s exploration and strategic layout in the nucleic acid drug field.
"New Eaglet Enterprises": Fostering New Momentum for Future Industries
"The New Eaglet" Enterprise Cultivation Plan Aims to Build the "Seed Corps" of Future Industries, Focusing on Supporting a Group ofCutting-edge Technology、Core PatentAndGrowth PotentialA technology-oriented enterprise. As the core cultivation carrier for Hangzhou to build a future industrial ecosystem, the "New Eaglet" enterprise certification strictly benchmarks against the requirements of disruptive technological innovation and high-quality development. The selected enterprises will receive multiple supports in terms of policies, funding, and resources, and further enhance their brand influence and social credibility, becoming the "rising stars" of urban innovation.
Driven by Technological Innovation, Showcasing Growth Potential
As an innovative biopharmaceutical company focusing on the research and development of small nucleic acid drugs, YOUJIA BIO has independently built the SEQUAD nucleic acid drug full-process R&D platform, covering key aspects such as sequence design, drug delivery, candidate screening, and functional verification, forming a comprehensive R&D system and project pipeline.
Currently, the company's pipeline covers several major disease areas such as cardiovascular, metabolic, anti-fibrosis, and antiviral, with over 30 proprietary intellectual properties. Relying on this technology platform, YOUJIA BIO has established cooperative relationships with multiple leading pharmaceutical enterprises, accelerating the translation path of nucleic acid drugs from laboratory research to clinical development.
In 2025, the siRNA innovative drug YJH-012, independently developed by the company, has entered the clinical stage, marking the company's official transition from preclinical research to a new phase of clinical development. In terms of collaboration models and commercialization strategies, YOUJIA BIO is actively exploring in-depth partnerships with large pharmaceutical enterprises to promote the market application of innovative drugs in China and even globally.
Looking Ahead: Innovation Empowers, Focusing on Clinical Value
The selection as a "New Eaglet Enterprise" is not only an acknowledgment of YOUJIA BIO's technical accumulation and development potential but also an affirmation of the promising future of the nucleic acid drug sector. Moving forward, the company will continue to focus on the research and development of small nucleic acid drugs, strengthen its technological platform, expand diversified collaborations, and strive to provide innovative solutions for unmet clinical needs while contributing to Hangzhou’s ambition to become a global highland for biopharmaceutical innovation.